A Phase 3 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 207 sites in 28 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 2nd largest by enrollment, is the only one that started in 2010, is one of 21 in phase 3, and was the 15th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2010.
This study's enrollment of 768 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 5th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2010, is one of 74 in phase 3, and was the 70th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo tablets administered twice daily
Drug: Placebo · Drug: Antiepileptic drugs with market authorization available per country
Brivaracetam 50 mg/ day administered twice daily.
Drug: Brivaracetam · Drug: Antiepileptic drugs with market authorization available per country
Brivaracetam 100 mg/ day administered twice daily
Drug: Brivaracetam · Drug: Antiepileptic drugs with market authorization available per country
Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration
Primary endpoint: United States of America (FDA)
Time frame: 12 week Treatment Period
50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration
Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration.
Time frame: Baseline to 12 week Treatment Period
Percent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period
Time frame: Baseline to 12 week Treatment Period
Categorized Percent Reduction Form Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the Treatment Period
Time frame: Baseline to 12 week Treatment Period
Seizure Freedom Rate (All Seizure Types) During the 12-week Treatment Period
Time frame: 12 week Treatment Period
All Seizure Frequency (Type I + II + III) During the 12-week Treatment Period
Time frame: 12 week Treatment Period
Time to the First Type I Seizure During the Treatment Period
Time frame: 12 week Treatment Period
Time to the Fifth Type I Seizure During the Treatment Period
Time frame: 12 week Treatment Period
Time to the Tenth Type I Seizure During the Treatment Period
Time frame: 12 week Treatment Period
Recruitment for the N01358 study began in December 2010. The study concluded in May 2014.
| Milestone | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Started | 263 | 254 | 251 |
| Completed | 246 | 225 | 225 |
| Not completed | 17 | 29 | 26 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 4 |
| Withdrew: Sae, non-fatal | 1 | 5 | 1 |
| Withdrew: Ae, non-serious non-fatal | 9 | 15 | 13 |
| Withdrew: Sae, non-fatal+ae, non-serious non-fatal | 0 | 1 | 1 |
| Withdrew: Non compliance | 2 | 0 | 0 |
| Withdrew: Patient randomized by mistake | 0 | 1 | 0 |
| Withdrew: Erroneously randomized | 1 | 0 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 |
| Withdrew: Randomized in error | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Ae, serious fatal | 0 | 0 | 2 |
Primary endpoint: United States of America (FDA)
| Percentage of reduction | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Placebo |
|---|---|---|---|
| Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration | 22.8 | 23.2 | 0 |
Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration.
| Percentage of subjects | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Responders | 21.6 | 38.9 | 37.8 |
| Non-Responders | 78.4 | 61.1 | 62.2 |
| percentage of change | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Percent Change in Partial Onset Seizure (Type I) Frequency From the Baseline to the Treatment Period | 17.6 (-8.3 to 46.0) | 37.2 (0.1 to 69.4) | 35.6 (4.8 to 66.2) |
| percentage of subjects | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| <-25 % | 16.6 | 14.3 | 10.8 |
| -25 % to <25 % | 40.5 | 28.6 | 29.3 |
| 25 % to <50 % | 21.2 | 18.3 | 22.1 |
| 50 % to <75 % | 13.9 | 19.0 | 18.1 |
| 75 % to <100 % | 6.9 | 13.9 | 13.7 |
| 100 % | 0.8 | 6.0 | 6.0 |
| percentage of subjects | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Seizure free | 0.8 | 5.2 | 4.0 |
| No seizures but discontinued | 0.4 | 1.2 | 1.2 |
| Not seizure free | 98.8 | 93.7 | 94.8 |
| number of seizures/ 28-day | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| All Seizure Frequency (Type I + II + III) During the 12-week Treatment Period | 8.7 (4.3 to 23.6) | 6.3 (2.7 to 17.8) | 5.8 (2.3 to 14.2) |
| days | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Time to the First Type I Seizure During the Treatment Period | 3 (2 to 3) | 5 (3 to 7) | 6 (4 to 7) |
| days | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Time to the Fifth Type I Seizure During the Treatment Period | 16 (12 to 19) | 21 (17 to 25) | 23 (20 to 26) |
| days | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| Time to the Tenth Type I Seizure During the Treatment Period | 32 (24 to 36) | 37 (29 to 46) | 43 (36 to 49) |
Collected over Treatment-emergent Adverse Events (TEAE) were collected during the study up to week 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 9/261 (3.4%) | 61/261 (23.4%) |
| Brivaracetam 100 mg/Day | — | 8/253 (3.2%) | 96/253 (37.9%) |
| Brivaracetam 200 mg/Day | — | 8/250 (3.2%) | 97/250 (38.8%) |
| Event | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 0/261 | 1/253 | 2/250 |
| PneumoniaInfections and infestations | 1/231 | 0/253 | 0/250 |
| DeathGeneral disorders | 0/261 | 0/253 | 1/250 |
| Sudden unexplained death in epilepsyGeneral disorders | 0/261 | 0/253 | 1/250 |
| Localised infectionInfections and infestations | 0/261 | 0/253 | 1/250 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/261 | 0/253 | 1/250 |
| Humerus fractureInjury, poisoning and procedural complications | 0/261 | 0/253 | 1/250 |
| Grand mal convulsionNervous system disorders | 1/261 | 0/253 | 1/250 |
| Seizure clusterNervous system disorders | 0/261 | 0/253 | 1/250 |
| Adjustment disorderPsychiatric disorders | 0/261 | 1/253 | 1/250 |
| Event | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day |
|---|---|---|---|
| SomnolenceNervous system disorders | 20/261 | 49/253 | 42/250 |
| DizzinessNervous system disorders | 13/261 | 26/253 | 36/250 |
| FatigueGeneral disorders | 10/261 | 19/253 | 29/250 |
| HeadacheNervous system disorders | 22/261 | 17/253 | 20/250 |
| Urinary tract infectionInfections and infestations | 8/261 | 13/253 | 2/250 |
Baseline Characteristics consist of the Randomized Set (RS). The RS includes all subjects that were randomized.
| Age, Continuous(years) | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Total Title |
|---|---|---|---|---|
| Mean | 39.8 ± 12.8 | 39.0 ± 13.4 | 39.7 ± 12.8 | 39.5 ± 13.0 |
| Sex: Female, Male(Participants) | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Total Title |
|---|---|---|---|---|
| Female | 128 | 152 | 117 | 397 |
| Male | 135 | 102 | 134 | 371 |
| Weight(kilograms) | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Total Title |
|---|---|---|---|---|
| Median | 76.1 ± 19.9 | 74.1 ± 16.8 | 75.5 ± 19.0 | 75.2 ± 18.6 |
| Height(centimeters) | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Total Title |
|---|---|---|---|---|
| Mean | 168.4 ± 10.0 | 166.6 ± 9.8 | 168.7 ± 9.9 | 167.9 ± 9.9 |
| BMI(kg/m^2) | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Total Title |
|---|---|---|---|---|
| Mean | 26.6 ± 5.7 | 26.7 ± 5.6 | 26.4 ± 6.0 | 26.6 ± 5.8 |
| Racial Group(participants) | Placebo | Brivaracetam 100 mg/Day | Brivaracetam 200 mg/Day | Total Title |
|---|---|---|---|---|
| American Indian or Alaska Native | 10 | 8 | 11 | 29 |
| Asian | 32 | 32 | 29 | 93 |
| Black or African American | 11 | 8 | 7 | 26 |
| White | 190 | 183 | 183 | 556 |
| Other | 17 | 21 | 18 | 56 |
| Missing | 3 | 2 | 3 | 8 |
Showing the first 100 of 207 sites across 28 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2010, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 2 years 3 months after primary completion. A results delay was requested in Apr 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam